eo-adjuvant T-VEC + NivolumabAnti-PD-1 combination therapy for resectable early metastatic (stage IIIB/C/D-IV M1a) melanoma with injectable disease - NIVEC

Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 24 人开始时间: 2019年12月9日最近更新: 2020年10月13日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 24

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•- Adults at least 18 years of age
•- WHO performance score of 0 or 1
•- Cytologically or histologically confirmed diagnosis of stage IIIB/C/D/IVM1a (AJCC 8th edition) melanoma, eligible for surgical resection.
•- Subjects must have measurable disease according to RECIST 1.1 and must be a candidate for intralesional therapy with at least one injectable cutaneous, subcutane-ous or nodal melanoma lesion (= 10 mm in longest diameter) or with multiple injectable lesions that in aggregate have a longest diameter of = 10 mm.
•- Prior isolated limb perfusion (ILP) is allowed (= 12 weeks prior to enrollment)
•- Screening laboratory values must meet the following criteria:
•- WBC = 2.0x10^9/L, Neutrophils =1.5x10^9/L, Platelets =100 x10^9/L, Hemoglobin =5.5 mmol/L, Creatinine =1.5x ULN, AST = 1.5 x ULN, ALT = 1.5 x ULN, Bilirubin =1.5 X ULN
•- LDH < 2 x ULN
•- Women of childbearing potential (WOCBP) must use highly effective method(s) of contraception (see paragraph 5.2) during T-VEC and nivolumab treatement and for a period of 5 months after the last dose of nivolumab.
•- Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to en-rollment and within 24 hours prior to the start of Nivolumab
•- Men receiving nivolumab and who are sexually active with WOCBP should use contraception during treatment and for a period of 7 months after the last dose of nivolumab
•- Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year.
•- Women who are not of childbearing potential (i.e., who are postmenopausal), or sur-gically sterile as well as azoospermic men do not require contraception
•- Patient is capable of understanding and complying with the protocol requirements and has signed the Informed Consent document.
•- Inhaled or topical steroids, and adrenal replacement steroid < 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease
•- International normalization ratio (INR) or prothrombin time (PT) =1.5 x ULN, unless the subject is receiving anticoagulant therapy, in which case PT and partial thromboplastin time (PTT)/ activated PTT (aPTT) must be within therapeutic range of intended use of anticoagulants.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 20
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 4

排除标准

•- Liver, Bone, Lung, Brain or other Visceral Metastases.
•- No measurable lesion according to RECIST 1.1
•- Prior radiotherapy for melanoma
•- Prior systemic cancer therapies, including, but not limited to anti-CTLA-4, anti-PD-1, anti-PD-L1
•- No other malignancies, except adequately treated and a cancer-related life-expectancy of more than 5 years.
•- Patients will be excluded if they test positive for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody), indicating acute or chronic infection
•- Patients will be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
•- Underlying medical conditions that, in the Investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity or adverse events. History or evidence of active autoimmune disease that requires high dose systemic treatment (ie, with use of disease modifying agents, corticosteroids or immuno-suppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Evidence of clinically significant immunosuppression such as the following:
•- Primary immunodeficiency state such as Severe Combined Immunodeficiency Disease.
•- Concurrent opportunistic infection.
•- Receiving systemic immunosuppressive therapy (> 2 weeks) including oral steroid doses > 10 mg/day of prednisone or equivalent within 7 days prior to enrollment.
•- Active herpetic skin lesions or prior complications of HSV-1 infection (e.g., herpetic keratitis or encephalitis).
•- Requirement of intermittent or chronic systemic (intravenous or oral) treatment with an antiherpetic drug (e.g., acyclovir), other than intermittent topical use.
•- Previous treatment with talimogene laherparepvec or any other oncolytic virus.
•- Received live vaccine within 28 days prior to enrollment.
•- Subject has known sensitivity to talimogene laherparepvec or any of its components to be administered during dosing.
•- Female subject of childbearing potential who is unwilling to use highly effective method(s) of effective contraception during study treatment and through 5 months after the last dose of study medication (per protocol through 3 months after the last dose of talimogene laherparepvec and through 5 months after the last dose of nivolumab).
•- Sexually active subjects and their partners unwilling to use male or female latex condom to avoid potential viral transmission during sexual contact while on treatment and within 30 days after treatment with talimogene laherparepvec.
•- Subjects who are unwilling to minimize exposure with his/her blood or other body fluids to individuals who are at higher risks for HSV-1 induced complications such as immunosuppressed individuals, individuals known to have HIV infection, pregnant women, or infants under the age of 3 months, during talimogene laherparepvec treatment and through 30 days after the last dose of talimogene laherparepvec.
•- No Allergies and Adverse Drug Reaction?
•- History of allergy to study drug components?
•- History of severe hypersensitivity reaction to any monoclonal antibody
•- No underlying medical conditions that, in the Investigator's opinion, will make the ad-ministration of study drug hazardous or obscure the interpretation of to

研究者

发起方

Antoni van Leeuwenhoek Ziekenhuis

相似试验

招募中

2 期

eo-adjuvant T-VEC + Nivolumab combination therapy for resectable early metastatic (stage IIIB/C/D-IV M1a) melanoma with injectable disease.skin cancerMelanoma

NL-OMON49074Antoni van Leeuwenhoek Ziekenhuis24

进行中（未招募）

1 期

EOpredict-Lung is a clinical study in subjects with histologically or cytologically confirmed, early stage or locally advanced non-small cell lung cancer (NSCLC) eligible for curative resection. This study will determine the feasibility of two cycles of preoperative immunotherapy with nivolumab or as combination nivolumab plus relatlimab.non-small cell lung cancer (NSCLC) of clinical stages IB, II and selected stage III AMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2019-002478-29-DEniversity Hospital Essen60

招募中

2 期

Neoadjuvant nivolumab combination treatment in resectable non-small cell lung cancer patients: Defining optimal combinations and determinants of immunological response (NEOpredict-Lung)

2024-513074-22-00Universitaetsklinikum Essen AöR, Universitaetsklinikum Essen AöR90

进行中（未招募）

1 期

EUCTR2019-002478-29-BEniversity Hospital Essen60

招募中

2 期

eoadjuvant nivolumab combination treatment in resectable non-small cell lung cancer patients: Defining optimal combinations and determinants of immunological responselungcancerNon small cell lung cancer100386661002910710038737

NL-OMON52539niversity Hospital Essen10